These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15918771)

  • 1. Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science.
    Schang LM
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):145-9. PubMed ID: 15918771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
    Schang LM
    Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
    Schang LM; St Vincent MR; Lacasse JJ
    Antivir Chem Chemother; 2006; 17(6):293-320. PubMed ID: 17249245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation.
    Sielecki TM; Boylan JF; Benfield PA; Trainor GL
    J Med Chem; 2000 Jan; 43(1):1-18. PubMed ID: 10633033
    [No Abstract]   [Full Text] [Related]  

  • 5. Herpes simplex viruses in antiviral drug discovery.
    Schang LM
    Curr Pharm Des; 2006; 12(11):1357-70. PubMed ID: 16611120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
    Schang LM
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):197-209. PubMed ID: 15023361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis.
    Moffat JF; McMichael MA; Leisenfelder SA; Taylor SL
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):225-31. PubMed ID: 15023363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinases as cellular targets for antiviral drugs.
    Schang LM
    J Antimicrob Chemother; 2002 Dec; 50(6):779-92. PubMed ID: 12460995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs.
    Schang LM
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):29-37. PubMed ID: 15777196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design of polymerase inhibitors as antiviral drugs.
    Oberg B
    Antiviral Res; 2006 Sep; 71(2-3):90-5. PubMed ID: 16820225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues.
    Pei XH; Xiong Y
    Oncogene; 2005 Apr; 24(17):2787-95. PubMed ID: 15838515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drug discovery and development: where chemistry meets with biomedicine.
    De Clercq E
    Antiviral Res; 2005 Aug; 67(2):56-75. PubMed ID: 16046240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
    Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of cell cycle blockage of hepatoma SK-Hep-1 cells by Epimedin C through suppression of mitogen-activated protein kinase activation and increased expression of CDK inhibitors p21(Cip1) and p27(Kip1).
    Liu TZ; Chen CY; Yiin SJ; Chen CH; Cheng JT; Shih MK; Wang YS; Chern CL
    Food Chem Toxicol; 2006 Feb; 44(2):227-35. PubMed ID: 16112786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibitors of picornavirus replication.
    De Palma AM; Vliegen I; De Clercq E; Neyts J
    Med Res Rev; 2008 Nov; 28(6):823-84. PubMed ID: 18381747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.